Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis

Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis

ABSTRACTPsoriasis, an immune-mediated inflammatory disease, affects nearly 125 million people globally. The interleukin (IL)-17A homodimer is a key driver of psoriasis and other autoimmune diseases, including psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa, and uveitis. Treatm...

Full description

Bibliographic Details
Main Authors: Susanne Klint, Joachim Feldwisch, Lindvi Gudmundsdotter, Karin Dillner Bergstedt, Elin Gunneriusson, Ingmarie Höidén Guthenberg, Anders Wennborg, Andrew C. Nyborg, Amol P. Kamboj, Paul M. Peloso, David Bejker, Fredrik Y. Frejd
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:mAbs
Subjects:
ABY-035
first-in-human
IL-17A inhibition
izokibep
psoriasis
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2023.2209920

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2023.2209920

Similar Items